Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

Study reports a highly attenuated SARS-CoV-2 that could serve as a live-attenuated vaccine platform

The research showed a highly attenuated SARS-CoV-2 strain that might be used as a live-attenuated vaccine platform and a BSL-2 experimental system.

18 Feb 2022

Response of peripheral immune cells to ex vivo SARS-CoV-2 exposure compared to SARS-CoV

Researchers characterized the responses of the PBMCs at the individual cell and cell type levels against SARS-CoV-2 and SARS-CoV ex vivo.

18 Feb 2022

Impact of several ACE2 coding missense variants and their effect on ACE2 protein subcellular localization and trafficking

Researchers investigated the connecting link between viral genetic variability and clinical heterogeneity of COVID-19 by analyzing the effect of several missense mutations on the ACE2 receptor coding sequence.

18 Feb 2022

mRNA vaccine-induced antibodies shown to be more effective in neutralizing SARS-CoV-2 and its variants than natural immunity

Researchers designed an electrochemiluminescence-based serology test with remarkable sensitivity to precisely quantify the amounts of anti-RBD antibodies in individuals infected with SARS-CoV-2.

18 Feb 2022

A novel consensus-based computational pipeline that reliably predicts hACE2-RBD binding affinity

Researchers developed a novel computational model to predict the binding affinity between the hACE2 receptor and the RBD of S protein of SARS-CoV-2.

17 Feb 2022

Study suggests tea polyphenols may modulate COVID-19 via intestinal microbiota

A new study discusses the state of current knowledge about the potential use of tea polyphenols in the prevention and treatment of COVID-19.

16 Feb 2022

Children with severe COVID-19 show low mucosal neutralizing activity against SARS-CoV-2

A new study examines neutralizing responses to the ancestral variant of SARS-CoV-2, as well as against later variants of concern.

16 Feb 2022

Study explores how the electrostatic charge of the SARS-CoV-2 spike protein has changed over time

In a new study, researchers examined the effect of electrostatic changes on the ability of the SARS-CoV-2 Omicron variant to escape immunity.

16 Feb 2022

Omicron RBD-ACE2 binding found to be stronger than wild type SARS-CoV-2 strain

Researchers recently investigated the effect of SARS-CoV-2 Omicron variant mutations on the binding of the receptor-binding domain and angiotensin-converting enzyme-2 to study the overall binding profile of the RBD-ACE2 system.

16 Feb 2022

Research suggests SARS-CoV-2 viral accessory proteins may play significant role in viral evolution

Researchers investigate SARS-CoV-2 mutations present across the whole genome of different SARS-CoV-2 variants.

15 Feb 2022

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Researchers study antibodies against various SARS-CoV-2 epitopes that may be responsible for neutralizing activities in recovered COVID-19 patients.

15 Feb 2022

Structural protein vimentin facilitates SARS-CoV-2 entry into endothelial cells

Researchers suggest that extracellular vimentin may act as a coreceptor to allow for SARS-CoV-2 entry into cells.

14 Feb 2022

Variations in the neutralization of SARS-CoV-2 variants in vaccinated mice and primates

In a new study, researchers demonstrated the variations in the neutralizing antibody responses induced by SARS-CoV-2 vaccines in humans, non-human primates, and mice against the SARS-CoV-2 variants of concern.

14 Feb 2022

Study describes a β-CoV spike protein target for protective antibodies that may facilitate pan-β-CoV vaccine development

In a recent study published in Science Translational Medicine, researchers characterized a human antibody targeting betacoronaviruses (β-CoVs).

14 Feb 2022

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

A new study was based on the hypothesis that competitively inhibiting cellular furin and selectively targeting SARS-CoV-2 in the infected viral-producing cells is critical for therapeutic specificity.

14 Feb 2022

Researchers identify autoantibody targets in COVID-19 patients

In a new study, researchers have been investigating auto-immune responses to natural human antigens in COVID-19 patients.

14 Feb 2022

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

In a study posted to the bioRxiv* preprint server, a team of researchers from the United States evaluated the protective effect of the preclinical version of the current Moderna Omicron-targeted mRNA-1273.529 vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 Omicron infection in mice.

14 Feb 2022

Nitazoxanide shows promise for COVID-19 treatment in animal model

In a recent study posted to the bioRxiv* pre-print server, researchers demonstrated that Nitazoxanide (NTZ), an oral drug, broadly inhibits replication of several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in preclinical models of infection.

13 Feb 2022

Testes found to be a viral reservoir for SARS-CoV-2 replication

In a recent study posted to the medRxiv* pre-print server, researchers used a suite of methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the testis of patients who died from coronavirus disease 2019 (COVID-19) to gain insights into SARS-CoV-2 tropism inside testis and its impact on male fertility.

13 Feb 2022

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

A recent paper by researchers from Australia, currently available on the medRxiv* preprint server, shows how Immunoglobulin A (IgA) antibodies in individuals who were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to the neutralization of the virus and its variants, even though this response is heterogeneous and less potent when compared to IgG antibodies.

13 Feb 2022

Angiotensin News and Research

Further Reading

Study reports a highly attenuated SARS-CoV-2 that could serve as a live-attenuated vaccine platform

Response of peripheral immune cells to ex vivo SARS-CoV-2 exposure compared to SARS-CoV

Impact of several ACE2 coding missense variants and their effect on ACE2 protein subcellular localization and trafficking

mRNA vaccine-induced antibodies shown to be more effective in neutralizing SARS-CoV-2 and its variants than natural immunity

A novel consensus-based computational pipeline that reliably predicts hACE2-RBD binding affinity

Study suggests tea polyphenols may modulate COVID-19 via intestinal microbiota

Children with severe COVID-19 show low mucosal neutralizing activity against SARS-CoV-2

Study explores how the electrostatic charge of the SARS-CoV-2 spike protein has changed over time

Omicron RBD-ACE2 binding found to be stronger than wild type SARS-CoV-2 strain

Research suggests SARS-CoV-2 viral accessory proteins may play significant role in viral evolution

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Structural protein vimentin facilitates SARS-CoV-2 entry into endothelial cells

Variations in the neutralization of SARS-CoV-2 variants in vaccinated mice and primates

Study describes a β-CoV spike protein target for protective antibodies that may facilitate pan-β-CoV vaccine development

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

Researchers identify autoantibody targets in COVID-19 patients

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

Nitazoxanide shows promise for COVID-19 treatment in animal model

Testes found to be a viral reservoir for SARS-CoV-2 replication

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News